CCP Virus Vaccine Likely Moving to Phase 2 Soon as Higher Dosing Starts

A pharmacist gives Jennifer Haller the first shot in the first-stage safety study clinical trial of a potential vaccine for COVID-19 at the Kaiser Permanente Washington Health Research Institute in Seattle on March 16, 2020. The vaccine was developed by Moderna. Ted S. Warren/AP Photo

A CCP virus vaccine will likely move to phase 2 testing as soon as safety data comes in from phase 1, Moderna CEO Stéphane Bancel said on April 14.

Moderna quickly developed an experimental vaccine against the CCP virus, commonly known as novel coronavirus, delivering the first doses to federal researchers in February. The first doses were given to volunteers the next month.